(Q48199689)

9 February 2018

title

Adriamycin and 1-(2-chlorethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in the treatment of metastatic breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A638989

17 July 2022

Adriamycin and 1-(2-Chlorethyl)-3-Cyclohexyl-1-Nitrosourea (CCNU) in the treatment of metastatic breast cancer (English)

1 reference

10.1002/1097-0142(197804)41:4<1235::AID-CNCR2820410403>3.0.CO;2-8

https://api.crossref.org/works/10.1002/1097-0142(197804)41:4%3C1235::AID-CNCR2820410403%3E3.0.CO;2-8

28 August 2023

1 reference

1 reference

10.1002/1097-0142(197804)41:4<1235::AID-CNCR2820410403>3.0.CO;2-8

https://api.crossref.org/works/10.1002/1097-0142(197804)41:4%3C1235::AID-CNCR2820410403%3E3.0.CO;2-8

28 August 2023

author name string

W. C. Waterfield

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A638989

17 July 2022

C. K. Tashima

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A638989

17 July 2022

G. N. Hortobagyi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A638989

17 July 2022

G. R. Blumenschein

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A638989

17 July 2022

A. U. Buzdar

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A638989

17 July 2022

M. A. Burgess

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A638989

17 July 2022

language of work or name

English

0 references

publication date

1 April 1978

1 reference

9 February 2018

full work available at URL

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2F1097-0142(197804)41:4%3C1235::AID-CNCR2820410403%3E3.0.CO;2-8

1 reference

10.1002/1097-0142(197804)41:4<1235::AID-CNCR2820410403>3.0.CO;2-8

https://api.crossref.org/works/10.1002/1097-0142(197804)41:4%3C1235::AID-CNCR2820410403%3E3.0.CO;2-8

https://onlinelibrary.wiley.com/doi/full/10.1002/1097-0142(197804)41:4%3C1235::AID-CNCR2820410403%3E3.0.CO;2-8

28 August 2023

1 reference

10.1002/1097-0142(197804)41:4<1235::AID-CNCR2820410403>3.0.CO;2-8

https://api.crossref.org/works/10.1002/1097-0142(197804)41:4%3C1235::AID-CNCR2820410403%3E3.0.CO;2-8

28 August 2023

1 reference

9 February 2018

volume

41

1 reference

9 February 2018

page(s)

1235-1239

1 reference

9 February 2018

issue

4

1 reference

9 February 2018

Adriamycin. A new anticancer drug with significant clinical activity

cites work

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%28197804%2941%3A4%3C1235%3A%3AAID-CNCR2820410403%3E3.0.CO%3B2-8

Superiority of adriamycin over oral nitrosoureas in patients with advanced breast carcinoma.A southwest cancer chemotherapy study group study

21 January 2018

10

1 reference

10.1002/1097-0142(197804)41:4<1235::AID-CNCR2820410403>3.0.CO;2-8

https://api.crossref.org/works/10.1002/1097-0142(197804)41:4%3C1235::AID-CNCR2820410403%3E3.0.CO;2-8

Combination chemotherapy and adriamycin in patients with advanced breast cancer. A Southwest Oncology Group study

28 August 2023

11

1 reference

10.1002/1097-0142(197804)41:4<1235::AID-CNCR2820410403>3.0.CO;2-8

https://api.crossref.org/works/10.1002/1097-0142(197804)41:4%3C1235::AID-CNCR2820410403%3E3.0.CO;2-8

Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer

28 August 2023

13

1 reference

10.1002/1097-0142(197804)41:4<1235::AID-CNCR2820410403>3.0.CO;2-8

https://api.crossref.org/works/10.1002/1097-0142(197804)41:4%3C1235::AID-CNCR2820410403%3E3.0.CO;2-8

1,-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (methyl CCNU) and adriamycin combination therapy

28 August 2023

14

1 reference

10.1002/1097-0142(197804)41:4<1235::AID-CNCR2820410403>3.0.CO;2-8

https://api.crossref.org/works/10.1002/1097-0142(197804)41:4%3C1235::AID-CNCR2820410403%3E3.0.CO;2-8

Clinical trials with adriamycin

28 August 2023

15

1 reference

10.1002/1097-0142(197804)41:4<1235::AID-CNCR2820410403>3.0.CO;2-8

https://api.crossref.org/works/10.1002/1097-0142(197804)41:4%3C1235::AID-CNCR2820410403%3E3.0.CO;2-8

Phase II evaluation of adriamycin in human neoplasia

28 August 2023

16

1 reference

10.1002/1097-0142(197804)41:4<1235::AID-CNCR2820410403>3.0.CO;2-8

https://api.crossref.org/works/10.1002/1097-0142(197804)41:4%3C1235::AID-CNCR2820410403%3E3.0.CO;2-8

28 August 2023

Cancer Treatment Reports

18

60

1687

Muss

1976

1 reference

10.1002/1097-0142(197804)41:4<1235::AID-CNCR2820410403>3.0.CO;2-8

https://api.crossref.org/works/10.1002/1097-0142(197804)41:4%3C1235::AID-CNCR2820410403%3E3.0.CO;2-8

28 August 2023

Identifiers

10.1002/1097-0142(197804)41:4<1235::AID-CNCR2820410403>3.0.CO;2-8

1 reference

9 February 2018

1 reference

9 February 2018